Comparative Pharmacology
Head-to-head clinical analysis: DEXAIR versus HYDROCORTONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXAIR versus HYDROCORTONE.
DEXAIR vs HYDROCORTONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DEXAIR (dexamethasone) is a corticosteroid that binds to the glucocorticoid receptor, leading to modulation of gene expression and suppression of inflammatory mediators (e.g., cytokines, prostaglandins). It also inhibits leukocyte infiltration and reduces capillary permeability.
Hydrocortisone is a corticosteroid that binds to the glucocorticoid receptor, leading to anti-inflammatory and immunosuppressive effects by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppressing cytokine production.
Inhalation: 2 inhalations (80 mcg each) twice daily, maximum 640 mcg/day.
100-500 mg intravenously every 2-6 hours for initial management of adrenal insufficiency; oral maintenance: 20-30 mg daily in divided doses (e.g., 10 mg morning, 5 mg afternoon).
None Documented
None Documented
Terminal elimination half-life: 3.0-4.5 hours in adults with normal renal function; prolonged to 8-12 hours in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life: 1.5–2.5 hours (plasma), but biological half-life (duration of HPA axis suppression) is 8–12 hours.
Renal (urinary): ~65-75% as unchanged drug and metabolites; biliary/fecal: ~20-30% as metabolites; less than 10% unchanged in bile.
Renal (primarily as inactive metabolites; <5% unchanged) and biliary/fecal (minor).
Category C
Category C
Corticosteroid
Corticosteroid